‘Altered Experience’ Fund Brings Psychedelics to U.S. ETFs
- Defiance’s PSY tracks medical uses of legal psychedelics
- Follows launch of a similar Canadian fund in January
Photographer: Brent Lewin/Bloomberg
This article is for subscribers only.
Curious investors looking for new experiences in the $6.3 trillion U.S. exchange-traded fund market can now dabble in the world of psychedelic drugs.
The Defiance Next Gen Altered Experience ETF began trading Friday under the ticker PSY, offering exposure to firms involved in “the next generation of medicine, including psychedelics, cannabis and other psychedelic-derived treatments,” according to a statement.